Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
This study was an open efficacy and safety study of teicoplanin in hospitalized patients with gram-positive infections. 26 patients entered the study. Teicoplanin was administered by intravenous bolus injection at a dose of 200 mg or 400 mg every 24 h, and in all cases an initial loading dose of 400 mg was given. The mean duration of treatment was 9.4 days (range four to 20 days). The infections included 18 skin/soft tissue, four lower respiratory tract, two urinary tract and two joint/bone. Clinical cure and improvement occurred in 20 of the 26 patients. Only two adverse events (moderate diarrhoea and mild pain at injection site) related to teicoplanin occurred in one patient. It was concluded that teicoplanin was effective and well tolerated in the treatment of gram-positive infections.
Kempf
P
P
Chirurgische Abteilung, Stadtkrankenhaus, Rüsselsheim.
Pompetzki
H
H
Oppermann
A
A
Wittenberger
R
R
Siebert
J
J
Fell
J J
JJ
Dieterich
H A
HA
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002986:Clinical Trials as Topic; D005260:Female; D006020:Glycopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006094:Gram-Positive Bacteria; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D017334:Teicoplanin
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin